{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:05:43Z","timestamp":1790186743202,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,31]],"date-time":"2027-08-31T00:00:00Z","timestamp":1819670400000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK135515"],"award-info":[{"award-number":["R01 DK135515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.diabres.2026.113504","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:50:40Z","timestamp":1787241040000},"page":"113504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trends in utilization of glucagon-like peptide\u20111 receptor agonists, sodium\u2013glucose cotransporter\u20112 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity"],"prefix":"10.1016","volume":"240","author":[{"given":"Paige D.","family":"Wartko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Begle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-5897","authenticated-orcid":false,"given":"Jennifer F.","family":"Bobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4491-1880","authenticated-orcid":false,"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arterburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113504_b0005","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S27-S49. doi: 10.2337\/dc26-S002.","DOI":"10.2337\/dc26-S002"},{"key":"10.1016\/j.diabres.2026.113504_b0010","unstructured":"Centers for Disease Control and Prevention. \u201cNational Diabetes Statistics Report.\u201d US Department of Health and Human Services. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html (accessed May 25, 2025)."},{"key":"10.1016\/j.diabres.2026.113504_b0015","doi-asserted-by":"crossref","unstructured":"P. J. Dyck et al., \u201cThe prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study,\u201d Neurology, vol. 43, no. 4, pp. 817-24, Apr 1993. [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8469345.","DOI":"10.1212\/WNL.43.4.817"},{"key":"10.1016\/j.diabres.2026.113504_b0020","unstructured":"Centers for Disease Control and Prevention. \u201cRisk Factors for Diabetes-Related Complications.\u201d U.S. Department of Health & Human Services. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/risks-complications.html (accessed Feb 10, 2023)."},{"key":"10.1016\/j.diabres.2026.113504_b0025","doi-asserted-by":"crossref","unstructured":"M. Serrano Rios, \u201cRelationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus,\u201d (in eng), Eur J Clin Invest, vol. 28 Suppl 2, pp. 14-7, discussion 17-8, Sep 1998, doi: 10.1046\/j.1365-2362.1998.0280s2014.x.","DOI":"10.1046\/j.1365-2362.1998.0280s2014.x"},{"key":"10.1016\/j.diabres.2026.113504_b0030","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S216-S245. doi: 10.2337\/dc26-S010.","DOI":"10.2337\/dc26-S010"},{"issue":"24","key":"10.1016\/j.diabres.2026.113504_b0035","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113504_b0040","doi-asserted-by":"crossref","unstructured":"L. Ji et al., \u201cPrimacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients,\u201d Am J Med, vol. 126, no. 10, pp. 925 e11-22, Oct 2013, doi: 10.1016\/j.amjmed.2013.02.035.","DOI":"10.1016\/j.amjmed.2013.02.035"},{"key":"10.1016\/j.diabres.2026.113504_b0045","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes, \u201c1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes\u20142026,\u201d Diabetes care, vol. 49, no. Supplement_1, pp. S13-S26, 2026, doi: 10.2337\/dc26-S001.","DOI":"10.2337\/dc26-S001"},{"key":"10.1016\/j.diabres.2026.113504_b0050","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes, \u201c8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes\u20132026,\u201d Diabetes care, vol. 49, no. Supplement_1, pp. S166-S182, 2026, doi: 10.2337\/dc26-S008.","DOI":"10.2337\/dc26-S008"},{"key":"10.1016\/j.diabres.2026.113504_b0055","doi-asserted-by":"crossref","unstructured":"R. Singhal et al., \u201cEffect of COVID-19 pandemic on global Bariatric surgery PRActiceS - The COBRAS study,\u201d (in eng), Obes Res Clin Pract, vol. 15, no. 4, pp. 395-401, Jul-Aug 2021, doi: 10.1016\/j.orcp.2021.04.005.","DOI":"10.1016\/j.orcp.2021.04.005"},{"key":"10.1016\/j.diabres.2026.113504_b0060","doi-asserted-by":"crossref","unstructured":"H. Irfan, \u201cObesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial,\u201d (in eng), Curr Probl Cardiol, vol. 49, no. 1 Pt A, p. 102060, Jan 2024, doi: 10.1016\/j.cpcardiol.2023.102060.","DOI":"10.1016\/j.cpcardiol.2023.102060"},{"issue":"13","key":"10.1016\/j.diabres.2026.113504_b0065","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"\u201cTirzepatide for the Treatment of Obstructive sleep Apnea and Obesity,\u201d (in eng)","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2026.113504_b0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.diabres.2026.113504_b0075","unstructured":"OptumLabs., \u201cOptumLabsandOptumLabsData Warehouse (OLDW) Descriptions and Citation,\u201d ed. Eden Prairie, Minnesota, U.S.A, 2024."},{"issue":"9","key":"10.1016\/j.diabres.2026.113504_b0080","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/03007995.2018.1477747","article-title":"A systematic literature review comparing methods for the measurement of patient persistence and adherence","volume":"34","author":"Forbes","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.diabres.2026.113504_b0085","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/03007995.2017.1321534","article-title":"Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications","volume":"33","author":"Malo","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.diabres.2026.113504_b0090","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1111\/bcp.15391","article-title":"Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS","volume":"88","author":"Dalli","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.diabres.2026.113504_b0195","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11606-017-4095-x","article-title":"Hospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic events","volume":"32","author":"McCoy","year":"2017","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.diabres.2026.113504_b0095","doi-asserted-by":"crossref","unstructured":"R. Adhikari et al., \u201cNational Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020,\u201d J Am Heart Assoc, vol. 11, no. 9, p. e023811, May 3 2022, doi: 10.1161\/JAHA.121.023811.","DOI":"10.1161\/JAHA.121.023811"},{"key":"10.1016\/j.diabres.2026.113504_b0100","doi-asserted-by":"crossref","unstructured":"P. Li, J. S. Varghese, M. K. Shah, R. J. Galindo, F. J. Pasquel, M. K. Ali, and H. Shao, \u201cPrescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity,\u201d JAMA network open, vol. 8, no. 10, p. e2540890, Oct 1 2025, doi: 10.1001\/jamanetworkopen.2025.40890.","DOI":"10.1001\/jamanetworkopen.2025.40890"},{"issue":"5","key":"10.1016\/j.diabres.2026.113504_b0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","article-title":"Trends in utilization of Glucose- and Weight-Lowering Medications after Tirzepatide Approval in the United States : a Population-based Cohort Study","volume":"178","author":"Ostrominski","year":"2025","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113504_b0110","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.diabres.2026.113504_b0115","doi-asserted-by":"crossref","unstructured":"S. D. Emmerich, C. D. Fryar, B. Stierman, and C. L. Ogden, \u201cObesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023,\u201d NCHS Data Brief, no. 508, Sep 2024, doi: 10.15620\/cdc\/159281.","DOI":"10.15620\/cdc\/159281"},{"issue":"7","key":"10.1016\/j.diabres.2026.113504_b0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for Obesity: a Review","volume":"332","author":"Gudzune","year":"2024","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.diabres.2026.113504_b0125","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/jama.2026.0287","article-title":"Data on 3 New GLP-1 drugs for Weight loss that May Be Approved this Year","volume":"335","author":"Rubin","year":"2026","journal-title":"J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.diabres.2026.113504_b0130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/dom.70219","article-title":"Glucagon-like peptide-1 receptor agonist versus sodium-glucose cotransporter-2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity","volume":"28","author":"Bowe","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113504_b0135","doi-asserted-by":"crossref","unstructured":"P. J. Rodriguez et al., \u201cDiscontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity,\u201d (in eng), JAMA network open, vol. 8, no. 1, p. e2457349, Jan 2 2025, doi: 10.1001\/jamanetworkopen.2024.57349.","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"issue":"5","key":"10.1016\/j.diabres.2026.113504_b0140","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/dom.16290","article-title":"Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113504_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.diabres.2026.113504_b0150","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/M21-4284","article-title":"\u201cSodium-Glucose Cotransporter-2 Inhibitors in patients with Heart failure : a Systematic Review and Meta-analysis,\u201d (in eng)","volume":"175","author":"Zou","year":"2022","journal-title":"Ann Intern Med"},{"issue":"10365","key":"10.1016\/j.diabres.2026.113504_b0155","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.diabres.2026.113504_b0160","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"\u201cLong-Term Effects of Empagliflozin in patients with Chronic Kidney Disease,\u201d (in eng)","volume":"392","author":"Herrington","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113504_b0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113504_b0170","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once Weekly in patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.diabres.2026.113504_b0175","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamasurg.2025.3089","article-title":"Use of Glucagon-like Peptide-1 Agonists among individuals Undergoing Bariatric Surgery in the US","volume":"160","author":"Kim","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabres.2026.113504_b0180","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes, \u201c9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142026,\u201d Diabetes care, vol. 49, no. Supplement_1, pp. S183-S215, 2026, doi: 10.2337\/dc26-S009.","DOI":"10.2337\/dc26-S009"},{"issue":"2","key":"10.1016\/j.diabres.2026.113504_b0185","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/oby.23647","article-title":"\u201cIdentifying barriers to shared decision-making about bariatric surgery in two large health systems,\u201d (in eng)","volume":"31","author":"Arterburn","year":"2023","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.diabres.2026.113504_b0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"\u201cCompounded GLP-1 and dual GIP\/GLP-1 Receptor Agonists: a Statement from the American Diabetes Association,\u201d (in eng)","volume":"48","author":"Neumiller","year":"2025","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:23:45Z","timestamp":1790184225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726004249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0168822726004249"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113504","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in utilization of glucagon-like peptide\u20111 receptor agonists, sodium\u2013glucose cotransporter\u20112 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113504"}}